Hepatitis B Reactivation in Patients Treated with Direct-Acting Antivirals for Hepatitis C

Basit Öğe Kaydı
dc.contributor.authorToka, Bilal
dc.contributor.authorKoksal, Aydin Seref
dc.contributor.authorDertli, Ramazan
dc.contributor.authorSirin, Goktug
dc.contributor.authorFidan, Sami
dc.contributor.authorUlger, Yakup
dc.contributor.authorHarmandar, Ferda
dc.date.accessioned2024-02-23T14:26:41Z
dc.date.available2024-02-23T14:26:41Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractIntroduction: There is limited research about HBV reactivation (HBVr) due to direct-acting antivirals (DAA) for HCV and most are limited by short duration of follow-up, small sample size, and absence of baseline HBV DNA. We aimed to determine the incidence and clinical course of HBVr in HBsAg and/or anti-HBcIgG positive patients treated with DAA for HCV. Methods: Seven centers retrospectively analyzed their database on HCV patients treated with DAA between 2015 and 2019. Patients with HBV coinfection or resolved HBV infection were enrolled. Serum transaminases, HBsAg, HBeAg, and HBV DNA were followed every 4 weeks during DAA treatment and every 12 weeks 1 year after treatment. Entecavir or tenofovir disoproxil fumarate was started in case of HBVr. The development of HBVr, HBV flare, liver failure, and mortality were determined. Results: 852 patients received DAA treatment for HCV. Among them, 35 (4.1%) had HBV coinfection and 246 (28.9%) had resolved HBV infection. 257 patients (53.3% male, mean age: 63 +/- 9) constituted the study group (29 with coinfection and 228 with resolved infection). Three patients with coinfection were HBV DNA positive. HBVr developed in 10 (34.5%) HBsAg positive patients, either during (n = 3) or 12-48 weeks after finishing DAA treatment. HBV flare and acute liver failure developed in 1 patient (3.4%), each. Two patients with resolved infection developed HBVr (0.87%) and one (0.44%) had HBV flare. Overall, none of the patients died or underwent liver transplantation due to HBVr. Conclusion: Patients with HBV/HCV coinfection have a high risk of HBVr after DAA treatment and should receive antiviral prophylaxis. Patients with resolved infection have a low risk of HBVr and can be monitored by serial ALT measurements.en_US
dc.identifier.doi10.1159/000521298
dc.identifier.issn0257-2753
dc.identifier.issn1421-9875
dc.identifier.pmid35108715en_US
dc.identifier.scopus2-s2.0-85137154317en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1159/000521298
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14291
dc.identifier.wosWOS:000886943800001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofDigestive Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatitis Cen_US
dc.subjectHepatitis Ben_US
dc.subjectCoinfectionen_US
dc.subjectDaa Treatmenten_US
dc.subjectHbv Reactivationen_US
dc.subjectHepatitisen_US
dc.titleHepatitis B Reactivation in Patients Treated with Direct-Acting Antivirals for Hepatitis Cen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu